Ashland Presents Scientific Studies for Drug Formulation

Published on: 

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-11-04-2015, Volume 11, Issue 11

Ashland presented a science-based strategy to enhance pharmaceutical formulation quality and advance drug delivery at AAPS 2015.

Ashland scientists presented posters and technical sessions on advancing drug delivery during the American Association of Pharmaceutical Scientists (AAPS) annual meeting and exposition in Orlando, FL, Oct. 25–29, 2015.

During a presentation entitled, “Reducing Formulation Risk with Science-based Excipient Selection,” Thomas Durig, senior director of pharmaceutical and nutrition specialities, research and development, Ashland Specialty Ingredients, explained that rational selections of excipients require an understanding of structure-function and structure-property relationships of input material.

“Structure-function relationships can be defined as understanding how the chemical (or molecular) structure and the physical (or morphological) structure of a material impact physical and chemical properties that are critical to the end-use functionality,” he said.

Ashland utilizes structure-function models in its development laboratories to find or develop polymer excipients that serve to improve the manufacture and end-use functionality of specific drug products, the company reports.


Ashland presented eight technical posters that support a science-based approach to select and tailor products that optimize drug delivery through a variety of mechanisms. The poster sessions topics included process coating conditions, color stability issues, enhancing extrudability, polymeric carriers for amorphous solid dispersions, and functionality of HPMCAS in hot melt extrusion.

Source: Ashland